CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The B-cell chemokine, CXCL13, is a proposed serum biomarker of synovitis in RA. Its behaviour in the context of B-cell depletion therapy and reconstitution was studied during treatment of RA with rituximab. METHODS: Serum samples from 20 RA patients were analysed for CXCL13, RF-IgM and anti-CCP by ELISA before and 2 and 6 months following rituximab treatment. B cells were monitored by flow cytometry. Gene expression in blood and synovial biopsies was determined by qPCR. RESULTS: Patients with detectable B cells at 6 months had significantly higher levels of CXCL13 and RF-IgM and slightly higher levels of anti-CCP throughout the study, including at baseline, compared with patients with undetectable B cells at 6 months. Conversely, 10 of 12 patients with high baseline CXCL13 had detectable circulating B cells at 6 months, whereas no B cells could be detected at 6 months in patients with low baseline CXCL13. Synovial CXCL13 expression at baseline correlated significantly with serum CXCL13 levels, and the synovium of patients with high serum CXCL13 expressed elevated levels of IL-1β, IL-8, MMP1 and MMP3. In addition, synovial CXCL13 expression correlated significantly with several synovial inflammatory markers. CONCLUSIONS: Serum CXCL13 is predictive of the rate of B-cell repopulation following a course of rituximab in RA. Serum CXCL13 correlates with synovial CXCL13 measured at a single joint, suggesting synovitis as an important source of circulating CXCL13. Within the synovium, CXCL13 expression is highly correlated with markers of synovitis. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov/, NCT00147966.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Humby, F., Bombardieri, M., Manzo, A., Kelly, S., Blades, M. C., Kirkham, B., Spencer, J., & Pitzalis, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.0060001 · Cited by 537
Cited by
Pathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Dennis, G., Holweg, C. T., Kummerfeld, S. K., Choy, D. F., Setiadi, A. F., Hackney, J. A., Haverty, P. M., Gilbert, H., Lin, W. Y., Diehl, L., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4555 · Cited by 380
Self-citationDePianto, D. J., Chandriani, S., Abbas, A. R., Jia, G., N'Diaye, E. N., Caplazi, P., Kauder, S. E., Biswas, S., Karnik, S. K., Ha, C., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2013-204596 · Cited by 287
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2017) · Kelley and Firestein's Textbook of Rheumatology · doi:10.1016/b978-0-323-31696-5.00069-3 · Cited by 278
B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
Bugatti, S., Vitolo, B., Caporali, R., Montecucco, C., & Manzo, A. (2014) · BioMed Research International · doi:10.1155/2014/681678 · Cited by 170
Metadata
- Authors
- Rosengren, S., Wei, N., Kalunian, K. C., Kavanaugh, A., & Boyle, D. L.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-23
- Volume
- 50
- Issue
- 3
- Pages
- 603-610
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2098134859
- Cited by
- 71
- References
- 2
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/keq337
- The paper
- Rosengren, S., Wei, N., Kalunian, K. C., Kavanaugh, A., & Boyle, D. L. (2011). CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/keq337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.